Resistance to Lamivudine in HBV Egyptian Patients
|ClinicalTrials.gov Identifier: NCT01548820|
Recruitment Status : Completed
First Posted : March 8, 2012
Last Update Posted : September 10, 2013
|Condition or disease|
|Chronic Hepatitis B Virus Treatment|
Primarily: To study the correlations between the following parameters in adult Egyptian patients with chronic viral hepatitis B before treatment:
- HBV-DNA by quantitative PCR.
- Biopsy (if possible). Secondarily: After receiving lamivudine therapy we will identify the impact of these parameters on viral breakthrough at 1 year of therapy.
|Study Type :||Observational|
|Actual Enrollment :||230 participants|
|Official Title:||Pretreatment and On-treatment Indicators of Virologic Breakthrough in Chronic HBV Egyptian Patients Receiving Lamivudine Therapy|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||January 2013|
Chronic HBV Egyptian patients
chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
- Resistance to Lamivudine Therapy [ Time Frame: 1 year ]Prevelance of Lamivudine resistance among HBV Egyptian cases pretreatment and on treatment parameters for Lamivudine therapy resistance
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01548820
|Tropical medicine department|